Remove 2023 Remove Heart Disease Remove Tricuspid
article thumbnail

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

DAIC

Photo: Edwards Lifesciences milla1cf Fri, 02/02/2024 - 09:33 February 2, 2024 — Edwards Lifesciences Corporation announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).

Tricuspid 100
article thumbnail

Cardiac Reverse Remodeling and Changes in Heart Failure Indices After Transcatheter Tricuspid Valve Replacement in Adults With Congenital Heart Disease

Circulation: Cardiovascular Interventions

Background:There are limited data about changes in cardiac function (cardiac reverse remodeling) and heart failure indices after transcatheter tricuspid valve-in-valve replacement (TT-VIVR).

article thumbnail

The Society of Thoracic Surgeons Launches New Valve Surgery Risk Calculators

DAIC

milla1cf Tue, 04/30/2024 - 13:03 April 30, 2024 — The expanding use of transcatheter technologies has changed the landscape in the treatment of valvular disease in adult cardiac patients, with valve surgery rapidly shifting to more complex interventions frequently involving other concomitant procedures. and 4.1%, respectively.

TAVR 111
article thumbnail

Society of Cardiovascular Computed Tomography Annual Scientific Meeting SCCT24 Preview

DAIC

Attendees can join with their peers and participate in sessions on structural heart disease, congenital heart disease, guidelines and trials, AI/Machine learning, technical aspects of cardiac CT, coronary artery disease, vascular heart disease, debates and games and early career topics. 5:00 p.m.,

article thumbnail

TRiCares Announces Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Patient with a Pacemaker

DAIC

Tricuspid regurgitation (TR) is a common and serious disease for which open heart surgery and symptomatic pharmacologic treatment are the current standard treatment options. Owing to high mortality risk, access to open heart surgery is severely restricted and is not considered an option for most patients with TR.

article thumbnail

Physical Examination as a Helpful Aid in Decision-Making in Challenging ECGs

Dr. Smith's ECG Blog

His medical history includes hypertension, a decade-long battle with diabetes, ischemic heart disease, a coronary bypass graft surgery ten years ago, a diagnosis of congestive heart failure for the last five years, and a prior ICD implantation five years ago.

article thumbnail

A young lady with wide complex tachycardia. My first time actually making this diagnosis de novo in real life in the ED!

Dr. Smith's ECG Blog

There is mild-moderate tricuspid valve regurgitation. 756-764 Google Scholar == MY Comment , by K EN G RAUER, MD ( 6/3 /2023 ): == Today's case is gratifying — in that it illustrates an uncommon phenomenon that Dr. Meyers picked up with potential life-saving implications. The basal anterior wall and basal septum are hypokinetic.